BBOT announces new BBO-8520 data and combo strategy
BBOT says it has new BBO-8520 data, highlighting a focus on its BBO-8520 combination for 2L+ NSCLC and combo programs in KRAS-mutant cancers.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.